Pipeline and Clinical Trials
Endocrine & Metabolic
Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Relacorilant
Target Indication
Cushing syndrome
Currently in Phase Three
Compound
Miricorilant
Target Indication
NASH
Phase One Completed
Target Indication
Antipsychotic-induced weight gain
Phase Two
Oncology
Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Relacorilant + Nab-paclitaxel
Target Indication
Pancreatic cancer
Phase Two Completed
Target Indication
Ovarian cancer
Phase Two
Compound
Exicorilant + Enzalutamide1
Target Indication
Castration-resistant prostate cancer
Phase Two
Compound
Mifepristone + Enzalutamide 2
Target Indication
Castration-resistant prostate cancer
Phase Two
Compound
Mifepristone + Nab-paclitaxel1
Target Indication
Metastatic GR-positive triple-negative breast cancer
Phase Two
Compound
Mifepristone + Pembrolizumab1
Target Indication
Metastatic HER2-negative breast cancer
Phase Two
Compound
Relacorilant + Enzalutamide
Target Indication
Castration-resistant prostate cancer
Phase Two
Addiction
Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Mifepristone + Behavioral Therapy3
Target Indication
Alcohol use disorder
Phase Two
Ophthalmology
Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Mifepristone4
Target Indication
Central serous chorioretinopathy
Phase Two Completed
Neurology
Compound
Target Indication
Phase I
Phase II
Phase III
Compound
CORT113176
Target Indication
Amyotrophic lateral sclerosis (ALS)
Phase One
Psychiatry
Compound
Target Indication
Phase I
Phase II
Phase III
Compound
CORT108297
Target Indication
Post-traumatic stress disorder (PTSD)
Phase Two
Additional Areas of Research
Alzheimer’s disease
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Nonsmall cell lung cancer
Obesity
Osteoporosis
Obesity
Osteoporosis
GR, glucocorticoid receptor; HER2, human epidermal growth factor receptor 2; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; NASH, nonalcoholic steatohepatitis.
1Study sponsored by University of Chicago.
2Study sponsored by University of Chicago and the National Cancer Institute.
3Study sponsored by the Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism.
4Study sponsored by Bay Area Retina Associates and Ophthalmic Consultants of Boston.